hikma pharmaceuticals public limited company
hikma pharmaceuticals public limited company Company Information
Company Number
05557934
Next Accounts
Jun 2025
Industry
Manufacture of basic pharmaceutical products
Shareholders
-
Group Structure
View All
Contact
Registered Address
1 new burlington place, london, W1S 2HR
Website
www.hikma.comhikma pharmaceuticals public limited company Estimated Valuation
Pomanda estimates the enterprise value of HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY at £8.1b based on a Turnover of £2.3b and 3.49x industry multiple (adjusted for size and gross margin).
hikma pharmaceuticals public limited company Estimated Valuation
Pomanda estimates the enterprise value of HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY at £6.9b based on an EBITDA of £502.5m and a 13.8x industry multiple (adjusted for size and gross margin).
hikma pharmaceuticals public limited company Estimated Valuation
Pomanda estimates the enterprise value of HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY at £3.2b based on Net Assets of £1.8b and 1.81x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Hikma Pharmaceuticals Public Limited Company Overview
Hikma Pharmaceuticals Public Limited Company is a live company located in london, W1S 2HR with a Companies House number of 05557934. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in September 2005, it's largest shareholder is unknown. Hikma Pharmaceuticals Public Limited Company is a mature, mega sized company, Pomanda has estimated its turnover at £2.3b with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Hikma Pharmaceuticals Public Limited Company Health Check
Pomanda's financial health check has awarded Hikma Pharmaceuticals Public Limited Company a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
4 Weak
Size
annual sales of £2.3b, make it larger than the average company (£37.1m)
£2.3b - Hikma Pharmaceuticals Public Limited Company
£37.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 9%, show it is growing at a faster rate (5.2%)
9% - Hikma Pharmaceuticals Public Limited Company
5.2% - Industry AVG
Production
with a gross margin of 48.4%, this company has a lower cost of product (38.5%)
48.4% - Hikma Pharmaceuticals Public Limited Company
38.5% - Industry AVG
Profitability
an operating margin of 12.8% make it more profitable than the average company (6.8%)
12.8% - Hikma Pharmaceuticals Public Limited Company
6.8% - Industry AVG
Employees
with 8967 employees, this is above the industry average (108)
8967 - Hikma Pharmaceuticals Public Limited Company
108 - Industry AVG
Pay Structure
on an average salary of £54.6k, the company has an equivalent pay structure (£68k)
£54.6k - Hikma Pharmaceuticals Public Limited Company
£68k - Industry AVG
Efficiency
resulting in sales per employee of £257.4k, this is less efficient (£446.6k)
£257.4k - Hikma Pharmaceuticals Public Limited Company
£446.6k - Industry AVG
Debtor Days
it gets paid by customers after 100 days, this is later than average (56 days)
100 days - Hikma Pharmaceuticals Public Limited Company
56 days - Industry AVG
Creditor Days
its suppliers are paid after 75 days, this is slower than average (34 days)
75 days - Hikma Pharmaceuticals Public Limited Company
34 days - Industry AVG
Stock Days
it holds stock equivalent to 219 days, this is more than average (103 days)
219 days - Hikma Pharmaceuticals Public Limited Company
103 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 7 weeks, this is average cash available to meet short term requirements (9 weeks)
7 weeks - Hikma Pharmaceuticals Public Limited Company
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 52.8%, this is a higher level of debt than the average (45%)
52.8% - Hikma Pharmaceuticals Public Limited Company
45% - Industry AVG
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY financials
Hikma Pharmaceuticals Public Limited Company's latest turnover from December 2023 is £2.3 billion and the company has net assets of £1.8 billion. According to their latest financial statements, Hikma Pharmaceuticals Public Limited Company has 8,967 employees and maintains cash reserves of £164.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 2,307,939,311 | 2,020,550,694 | 1,956,621,704 | 1,794,144,697 | 2,207,000,000 | 1,679,240,691 | 1,529,346,710 | 1,415,505,226 | 1,113,000,464 | 1,030,592,470 | 897,612,941 | 656,795,973 | 609,335,590 | 439,053,340 | 440,475,828 |
| Other Income Or Grants | 0 | 0 | 0 | -9,196,812 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 1,192,100,827 | 1,026,731,958 | 959,534,028 | 864,500,307 | 1,119,000,000 | 827,451,935 | 765,463,307 | 699,767,712 | 480,754,367 | 441,583,610 | 395,212,731 | 358,306,189 | 346,924,200 | 224,406,535 | 229,932,222 |
| Gross Profit | 1,115,838,484 | 993,818,736 | 997,087,676 | 920,447,578 | 1,088,000,000 | 851,788,756 | 763,883,403 | 715,737,515 | 632,246,097 | 589,008,859 | 502,400,210 | 298,489,784 | 262,411,390 | 214,646,804 | 210,543,606 |
| Admin Expenses | 821,225,014 | 767,439,993 | 551,042,305 | 476,701,410 | 595,000,000 | 550,823,395 | 1,353,977,407 | 496,515,680 | 337,764,724 | 310,769,656 | 270,927,862 | 199,585,431 | 183,632,683 | 133,498,918 | 136,338,613 |
| Operating Profit | 294,613,470 | 226,378,743 | 446,045,371 | 443,746,168 | 493,000,000 | 300,965,361 | -590,094,004 | 219,221,835 | 294,481,373 | 278,239,203 | 231,472,348 | 98,904,353 | 78,778,707 | 81,147,886 | 74,204,993 |
| Interest Payable | 76,262,342 | 65,023,681 | 52,881,668 | 52,881,668 | 67,000,000 | 64,898,191 | 67,935,856 | 75,493,612 | 44,056,268 | 26,301,218 | 24,330,900 | 22,505,182 | 15,510,421 | 8,322,922 | 8,871,291 |
| Interest Receivable | 5,619,330 | 23,280,083 | 22,992,029 | 36,020,846 | 67,000,000 | 2,433,682 | 75,045,422 | 8,710,801 | 2,318,750 | 2,768,549 | 1,315,183 | 592,241 | 310,633 | 207,832 | 355,487 |
| Pre-Tax Profit | 225,575,981 | 187,043,429 | 416,922,134 | 427,651,747 | 491,000,000 | 237,689,624 | -582,984,438 | 152,439,024 | 245,787,602 | 250,553,710 | 195,962,386 | 78,175,896 | 62,320,457 | 72,670,591 | 65,555,709 |
| Tax | -71,445,773 | -33,715,983 | -95,033,722 | -98,099,326 | -4,000,000 | -6,489,819 | -79,785,133 | -37,746,806 | -49,466,687 | -55,370,986 | -53,922,536 | -14,806,041 | -6,918,226 | -12,887,434 | -10,698,527 |
| Profit After Tax | 154,130,208 | 153,327,446 | 321,888,412 | 329,552,422 | 487,000,000 | 231,199,805 | -662,769,571 | 114,692,218 | 196,320,915 | 195,182,724 | 142,039,850 | 63,369,855 | 55,402,230 | 59,783,157 | 54,857,182 |
| Dividends Paid | 109,978,325 | 100,345,187 | 91,968,118 | 83,537,707 | 97,000,000 | 68,143,101 | 62,406,193 | 55,894,309 | 49,466,687 | 38,067,553 | 25,646,084 | 15,990,524 | 16,727,068 | 13,859,322 | 11,147,382 |
| Retained Profit | 42,546,359 | 50,573,974 | 230,686,695 | 246,781,116 | 390,000,000 | 160,623,023 | -728,335,572 | 56,620,209 | 145,308,394 | 154,346,622 | 113,763,398 | 43,233,639 | 36,443,648 | 45,923,835 | 42,579,017 |
| Employee Costs | 489,684,515 | 476,037,569 | 446,811,772 | 429,184,549 | 520,000,000 | 410,481,058 | 383,126,629 | 337,543,554 | 279,795,950 | 238,095,238 | 209,771,816 | 174,119,041 | 157,864,729 | 101,487,866 | 108,080,780 |
| Number Of Employees | 8,967 | 8,835 | 8,703 | 8,681 | 8,578 | 8,413 | 8,521 | 8,339 | 7,189 | 7,139 | 7,067 | 6,521 | 6,165 | 5,396 | 4,880 |
| EBITDA* | 502,528,698 | 525,006,020 | 557,173,512 | 574,034,334 | 493,000,000 | 1,156,810,253 | -339,679,281 | 275,842,044 | 350,904,312 | 328,073,089 | 280,791,740 | 133,846,609 | 109,976,768 | 104,233,541 | 91,632,893 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,333,386,851 | 1,190,495,304 | 1,202,483,139 | 1,194,052,728 | 1,248,000,000 | 862,334,712 | 812,860,416 | 868,176,539 | 486,937,703 | 440,199,336 | 384,691,261 | 305,004,442 | 336,488,119 | 211,788,203 | 214,694,654 |
| Intangible Assets | 919,161,917 | 948,061,331 | 683,629,675 | 671,367,259 | 834,000,000 | 621,400,178 | 620,112,173 | 1,247,822,300 | 469,160,612 | 416,666,667 | 293,943,579 | 256,440,628 | 271,342,095 | 161,653,051 | 176,842,105 |
| Investments & Other | 8,027,614 | 8,027,614 | 43,684,855 | 36,787,246 | 43,000,000 | 55,163,462 | 52,136,818 | 39,924,505 | 40,964,599 | 38,067,552 | 36,825,145 | 6,514,657 | 8,017,390 | 7,108,360 | 5,714,779 |
| Debtors (Due After 1 year) | 264,108,533 | 206,309,705 | 140,251,379 | 169,374,616 | 243,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 2,071,124,668 | 1,984,426,426 | 1,745,861,434 | 1,696,045,370 | 2,082,000,000 | 1,483,734,890 | 1,432,972,588 | 2,115,998,838 | 956,098,315 | 856,866,002 | 678,634,839 | 561,445,069 | 607,830,213 | 373,441,254 | 391,536,759 |
| Stock & work in progress | 715,260,496 | 622,942,923 | 532,648,681 | 580,165,542 | 568,000,000 | 428,328,060 | 385,496,484 | 333,188,153 | 194,002,164 | 188,953,488 | 181,495,363 | 161,089,724 | 158,807,911 | 109,437,770 | 111,009,751 |
| Trade Debtors | 633,378,823 | 623,745,685 | 598,559,166 | 507,357,449 | 637,000,000 | 530,542,711 | 513,468,678 | 552,409,988 | 333,900,139 | 265,780,731 | 253,172,881 | 174,119,041 | 193,880,260 | 120,335,175 | 140,569,887 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 28,096,652 | 25,688,367 | 2,299,202 | 2,299,202 | 161,000,000 | 62,464,508 | 45,027,253 | 0 | 43,283,351 | 38,067,552 | 35,509,962 | 20,136,215 | 15,767,954 | 17,040,485 | 16,315,789 |
| Cash | 164,566,107 | 216,745,604 | 326,486,817 | 250,613,120 | 443,000,000 | 223,898,758 | 182,478,868 | 117,595,818 | 458,339,774 | 199,335,548 | 115,078,582 | 104,826,769 | 64,589,141 | 39,819,197 | 47,027,456 |
| misc current assets | 135,666,693 | 113,992,133 | 74,340,895 | 78,172,900 | 39,000,000 | 107,893,242 | 116,912,868 | 47,909,408 | 21,641,676 | 8,997,785 | 4,603,143 | 2,961,208 | 4,950,883 | 558,025 | 865,205 |
| total current assets | 1,685,799,149 | 1,604,720,238 | 1,604,843,654 | 1,473,022,685 | 1,848,000,000 | 1,353,127,282 | 1,243,384,154 | 1,051,103,368 | 1,051,167,105 | 701,135,105 | 589,859,933 | 463,132,958 | 437,996,150 | 287,190,654 | 315,788,090 |
| total assets | 3,756,923,817 | 3,589,146,664 | 3,350,705,088 | 3,169,068,055 | 3,930,000,000 | 2,836,862,172 | 2,676,356,742 | 3,167,102,206 | 2,007,265,420 | 1,558,001,107 | 1,268,494,772 | 1,024,578,027 | 1,045,826,363 | 660,631,908 | 707,324,849 |
| Bank overdraft | 0 | 0 | 2,299,203 | 2,299,203 | 0 | 60,030,827 | 67,935,856 | 7,259,001 | 88,885,454 | 272,009,967 | 3,945,551 | 11,844,833 | 12,137,263 | 48,663,503 | 41,715,886 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 248,053,303 | 233,603,596 | 200,797,057 | 213,825,874 | 286,000,000 | 213,352,803 | 172,209,495 | 124,854,820 | 107,435,461 | 89,285,714 | 78,911,028 | 65,146,580 | 64,885,172 | 45,012,013 | 39,634,138 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 120,414,224 | 111,583,848 | 39,086,450 | 67,443,286 | 569,000,000 | 0 | 0 | 31,939,605 | 0 | 0 | 42,085,881 | 7,106,899 | 46,187,441 | 0 | 0 |
| hp & lease commitments | 8,830,376 | 7,224,853 | 6,897,608 | 7,664,009 | 9,000,000 | 0 | 0 | 725,900 | 772,916 | 692,137 | 657,591 | 1,776,724 | 2,190,362 | 1,352,114 | 1,262,881 |
| other current liabilities | 697,599,740 | 512,161,834 | 529,583,075 | 496,627,833 | 607,000,000 | 451,042,425 | 389,446,241 | 501,596,979 | 260,473,023 | 220,099,665 | 259,748,797 | 190,701,804 | 132,761,181 | 56,716,120 | 58,781,380 |
| total current liabilities | 1,074,897,648 | 864,574,135 | 778,663,397 | 787,860,208 | 1,471,000,000 | 724,426,057 | 629,591,595 | 666,376,307 | 457,566,857 | 582,087,486 | 385,348,853 | 276,576,843 | 258,161,423 | 151,743,753 | 141,394,287 |
| loans | 1,653,688,688 | 1,822,268,602 | 612,354,383 | 640,711,219 | 166,000,000 | 1,178,713,391 | 1,346,077,888 | 1,077,235,771 | 946,050,393 | 232,558,138 | 370,881,830 | 459,579,508 | 481,918,225 | 101,102,833 | 169,851,302 |
| hp & lease commitments | 44,151,882 | 48,968,451 | 56,713,672 | 55,180,870 | 59,000,000 | 18,658,229 | 15,799,036 | 15,243,902 | 17,004,173 | 15,919,158 | 12,494,246 | 9,475,866 | 12,036,373 | 3,674,915 | 4,616,501 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 201,225 | 341,655 |
| other liabilities | 56,193,304 | 73,854,057 | 107,296,137 | 125,689,760 | 203,000,000 | 0 | 0 | 201,074,332 | 15,458,339 | 692,137 | 657,591 | 2,368,966 | 1,251,825 | 0 | 0 |
| provisions | 51,376,734 | 30,504,936 | 36,787,246 | 47,516,860 | 40,000,000 | 25,959,276 | 77,415,276 | 21,777,002 | 32,462,512 | 34,606,866 | 34,194,778 | 27,243,114 | 30,727,464 | 14,901,488 | 16,230,720 |
| total long term liabilities | 908,726,017 | 1,000,240,828 | 681,330,471 | 734,978,540 | 330,000,000 | 735,783,239 | 839,718,777 | 750,580,719 | 504,714,793 | 134,274,640 | 203,195,896 | 245,780,277 | 257,574,671 | 58,203,387 | 93,382,668 |
| total liabilities | 1,983,623,665 | 1,864,814,963 | 1,459,993,868 | 1,522,838,748 | 1,801,000,000 | 1,460,209,296 | 1,469,310,372 | 1,416,957,026 | 962,281,650 | 716,362,126 | 588,544,749 | 522,357,120 | 515,736,094 | 209,947,140 | 234,776,955 |
| net assets | 1,764,469,776 | 1,713,895,802 | 1,879,981,607 | 1,636,266,094 | 2,117,000,000 | 1,366,918,147 | 1,195,987,045 | 1,739,256,679 | 1,033,390,014 | 828,488,372 | 668,770,961 | 493,337,282 | 515,448,692 | 446,853,677 | 472,547,894 |
| total shareholders funds | 1,764,469,776 | 1,713,895,802 | 1,879,981,606 | 1,636,266,094 | 2,117,000,000 | 1,366,918,147 | 1,195,987,045 | 1,739,256,678 | 1,033,390,014 | 828,488,372 | 668,770,961 | 493,337,282 | 515,448,692 | 446,853,676 | 472,547,894 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 294,613,470 | 226,378,743 | 446,045,371 | 443,746,168 | 493,000,000 | 300,965,361 | -590,094,004 | 219,221,835 | 294,481,373 | 278,239,203 | 231,472,348 | 98,904,353 | 78,778,707 | 81,147,886 | 74,204,993 |
| Depreciation | 88,303,765 | 126,033,555 | 59,012,876 | 47,516,861 | 0 | 58,408,372 | 203,807,568 | 56,620,209 | 39,418,766 | 33,914,729 | 32,222,003 | 25,466,390 | 23,669,189 | 17,474,171 | 17,427,900 |
| Amortisation | 119,611,463 | 172,593,722 | 52,115,266 | 82,771,305 | 0 | 797,436,521 | 46,607,156 | 0 | 17,004,173 | 15,919,158 | 17,097,389 | 9,475,866 | 7,528,872 | 5,611,484 | 0 |
| Tax | -71,445,773 | -33,715,983 | -95,033,722 | -98,099,326 | -4,000,000 | -6,489,819 | -79,785,133 | -37,746,806 | -49,466,687 | -55,370,986 | -53,922,536 | -14,806,041 | -6,918,226 | -12,887,434 | -10,698,527 |
| Stock | 92,317,573 | 90,294,242 | -47,516,861 | 12,165,542 | 139,671,940 | 42,831,576 | 52,308,331 | 139,185,989 | 5,048,676 | 7,458,125 | 20,405,639 | 2,281,813 | 49,370,141 | -1,571,981 | 111,009,751 |
| Debtors | 69,840,250 | 114,634,010 | 62,078,480 | -361,968,732 | 447,992,781 | 34,511,288 | 6,085,943 | 175,226,498 | 73,335,207 | 15,165,440 | 94,427,587 | -15,392,958 | 72,272,554 | -19,510,016 | 156,885,676 |
| Creditors | 14,449,707 | 32,806,539 | -13,028,817 | -72,174,126 | 72,647,197 | 41,143,308 | 47,354,675 | 17,419,359 | 18,149,747 | 10,374,686 | 13,764,448 | 261,408 | 19,873,158 | 5,377,876 | 39,634,138 |
| Accruals and Deferred Income | 185,437,906 | -17,421,241 | 32,955,242 | -110,372,167 | 155,957,575 | 61,596,184 | -112,150,738 | 241,123,956 | 40,373,358 | -39,649,132 | 69,046,993 | 57,940,623 | 75,843,836 | -2,205,690 | 59,123,035 |
| Deferred Taxes & Provisions | 20,871,798 | -6,282,310 | -10,729,614 | 7,516,860 | 14,040,724 | -51,456,000 | 55,638,274 | -10,685,510 | -2,144,354 | 412,088 | 6,951,664 | -3,484,350 | 15,825,976 | -1,329,232 | 16,230,720 |
| Cash flow from operations | 489,684,513 | 295,464,773 | 456,774,983 | 650,708,765 | 143,980,775 | 1,124,261,063 | -487,016,476 | 171,540,556 | 279,432,493 | 221,216,181 | 201,799,083 | 186,869,394 | 92,958,817 | 114,271,058 | -71,973,168 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | -35,657,241 | 6,897,609 | -6,212,754 | -12,163,462 | 3,026,644 | 12,212,313 | -1,040,094 | 2,897,047 | 1,242,407 | 30,310,488 | -1,502,733 | 909,030 | 1,393,581 | 5,714,779 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 8,830,376 | 72,497,398 | -28,356,836 | -501,556,714 | 569,000,000 | 0 | -31,939,605 | 31,939,605 | 0 | -42,085,881 | 34,978,982 | -39,080,542 | 46,187,441 | 0 | 0 |
| Long term loans | -168,579,914 | 1,209,914,219 | -28,356,836 | 474,711,219 | -1,012,713,391 | -167,364,497 | 268,842,117 | 131,185,378 | 713,492,255 | -138,323,692 | -88,697,678 | -22,338,717 | 380,815,392 | -68,748,469 | 169,851,302 |
| Hire Purchase and Lease Commitments | -3,211,046 | -7,417,976 | 766,401 | -5,155,121 | 49,341,771 | 2,859,193 | -170,766 | -1,807,287 | 1,165,794 | 3,459,458 | 1,899,247 | -2,974,145 | 9,199,706 | -852,353 | 5,879,382 |
| other long term liabilities | -17,660,753 | -33,442,080 | -18,393,623 | -77,310,240 | 203,000,000 | 0 | -201,074,332 | 185,615,993 | 14,766,202 | 34,546 | -1,711,375 | 1,117,141 | 1,251,825 | 0 | 0 |
| share issue | |||||||||||||||
| interest | -70,643,012 | -41,743,598 | -29,889,639 | -16,860,822 | 0 | -62,464,509 | 7,109,566 | -66,782,811 | -41,737,518 | -23,532,669 | -23,015,717 | -21,912,941 | -15,199,788 | -8,115,090 | -8,515,804 |
| cash flow from financing | -243,236,734 | 983,148,184 | -91,201,716 | -853,686,700 | 168,710,233 | -216,661,734 | 227,832,919 | 929,397,333 | 747,279,981 | -195,077,449 | -14,876,260 | -150,534,254 | 454,405,944 | -149,333,965 | 597,183,757 |
| cash and cash equivalents | |||||||||||||||
| cash | -52,179,497 | -109,741,213 | 75,873,697 | -192,386,880 | 219,101,242 | 41,419,890 | 64,883,050 | -340,743,956 | 259,004,226 | 84,256,966 | 10,251,813 | 40,237,628 | 24,769,944 | -7,208,259 | 47,027,456 |
| overdraft | 0 | -2,299,203 | 0 | 2,299,203 | -60,030,827 | -7,905,029 | 60,676,855 | -81,626,453 | -183,124,513 | 268,064,416 | -7,899,282 | -292,430 | -36,526,240 | 6,947,617 | 41,715,886 |
| change in cash | -52,179,497 | -107,442,010 | 75,873,697 | -194,686,083 | 279,132,069 | 49,324,919 | 4,206,195 | -259,117,503 | 442,128,739 | -183,807,450 | 18,151,095 | 40,530,058 | 61,296,184 | -14,155,876 | 5,311,570 |
hikma pharmaceuticals public limited company Credit Report and Business Information
Hikma Pharmaceuticals Public Limited Company Competitor Analysis
Perform a competitor analysis for hikma pharmaceuticals public limited company by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in W1S area or any other competitors across 12 key performance metrics.
hikma pharmaceuticals public limited company Ownership
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY group structure
Hikma Pharmaceuticals Public Limited Company has 4 subsidiary companies.
Ultimate parent company
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
05557934
4 subsidiaries
hikma pharmaceuticals public limited company directors
Hikma Pharmaceuticals Public Limited Company currently has 11 directors. The longest serving directors include Mr Mazen Darwazah (Sep 2005) and Mr Ali Al Husry (Oct 2005).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Mazen Darwazah | United Kingdom | 66 years | Sep 2005 | - | Director |
| Mr Ali Al Husry | United Kingdom | 89 years | Oct 2005 | - | Director |
| Said Darwazah | United Kingdom | 67 years | Jul 2007 | - | Director |
| Mr John Castellani | United Kingdom | 74 years | Mar 2016 | - | Director |
| Ms Mary Henderson | United Kingdom | 74 years | Oct 2016 | - | Director |
| Ms Cynthia Flowers | United Kingdom | 65 years | Jun 2019 | - | Director |
| Mr Douglas Hurt | 68 years | May 2020 | - | Director | |
| Ms Laura Balan | England | 47 years | Oct 2022 | - | Director |
| Dr Deneen Vojta | United Kingdom | 60 years | Nov 2022 | - | Director |
| Ms Victoria Hull | 62 years | Nov 2022 | - | Director |
P&L
December 2023turnover
2.3b
+14%
operating profit
294.6m
+30%
gross margin
48.4%
-1.7%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
1.8b
+0.03%
total assets
3.8b
+0.05%
cash
164.6m
-0.24%
net assets
Total assets minus all liabilities
hikma pharmaceuticals public limited company company details
company number
05557934
Type
Public limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
September 2005
age
20
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
December 2023
previous names
hikma pharmaceuticals plc (October 2005)
hikma pharma public limited company (September 2005)
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
1 new burlington place, london, W1S 2HR
Bank
-
Legal Advisor
-
hikma pharmaceuticals public limited company Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to hikma pharmaceuticals public limited company. Currently there are 3 open charges and 0 have been satisfied in the past.
hikma pharmaceuticals public limited company Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY. This can take several minutes, an email will notify you when this has completed.
hikma pharmaceuticals public limited company Companies House Filings - See Documents
| date | description | view/download |
|---|
